Radiopharmaceuticals — Board Review Summary

PART I — FOUNDATIONS: THERANOSTICS, ISOTOPES, AND THE CURRENT LANDSCAPE

Core Definition

Targeted radionuclide therapy (TRT) delivers radiation systemically through a radiolabeled molecule, peptide, antibody, particle, or microparticle that either naturally accumulates in or is designed to target tumor. The key principle is that the therapeutic effect comes from absorbed radiation dose, not from the carrier molecule itself.

Theranostics

Radiopharmaceuticals are especially suited to a theranostic model: the same target can be used for diagnosis, treatment selection, dosimetry, response assessment, and therapy. This is one of the most board-relevant conceptual shifts in the field.

Alpha vs Beta Emitters

PropertyAlpha emittersBeta emitters
Examples225Ac, 227Th, 212Pb131I, 90Y, 177Lu, 223Ra
Physics advantageHigh LET, dense double-strand DNA damageCross-fire effect, broader dose deposition
Path-length advantageVery short path length, less normal tissue spillLonger path length, better for heterogeneous uptake
Key drawbackDose heterogeneity, daughter-decay toxicity, difficult imaging/dosimetryLower LET, more normal tissue spill than alpha emitters

Current Major Clinical Agents to Know

AgentMain diseaseTarget / mechanismBoard takeaway
I-131Differentiated thyroid cancerElemental iodine taken up by thyroid via NISHistoric proof that systemic targeted RT can improve survival
Y-90 microspheresPrimary liver tumors / liver-directed therapyIntra-arterial radioembolizationClassic locoregional radiopharma platform
Radium-223Bone-predominant mCRPCBone-seeking alpha-like calcium mimeticImproves OS in bone-only mCRPC
177Lu-DOTATATESSTR+ GEP-NETRadiolabeled somatostatin analogStandard PRRT platform for SSTR-positive NETs
177Lu-PSMA-617PSMA+ prostate cancerPSMA-targeted radioligand therapyNow a core therapy in mCRPC and moving earlier

Earlier / Foundational Radiopharmaceutical Platforms

I-131: thyroid tissue expresses the sodium-iodide symporter; 131I emits mostly beta radiation, has a half-life of about 8 days, roughly 2 mm penetration, and improves survival in metastatic thyroid cancer.
Y-90 radioembolization: leverages the fact that HCC is largely arterially supplied; 90Y has a half-life of about 2.5 days and about 2 cm beta range.

PART II — RADIUM-223

Indication and Practical Identity

Radium-223 dichloride (Xofigo) is approved for metastatic castration-resistant prostate cancer with bone-predominant disease. The deck specifically frames it as a radiopharmaceutical with meaningful survival benefit in the right bone-only mCRPC population.

ALSYMPCA

ALSYMPCA randomized 921 men with mCRPC, testosterone <50 ng/dL, and at least 2 bone metastases to 6 injections of Ra-223 every 4 weeks vs placebo. Dose was 50 kBq/kg (1.49 uCi/kg). Median OS improved from 11.3 to 14.9 months, median time to first skeletal event improved from 9.8 to 15.6 months, and time to alkaline phosphatase rise improved from 3.8 to 7.4 months. The study was stopped early for efficacy.

What to Monitor

ParameterPractical point
Main toxicity concernMarrow suppression
Common non-hematologic issuesNausea, vomiting, constipation, diarrhea; drug is cleared through liver/bile so stool is radioactive
Response markerPSA and bone scan correlate poorly; alkaline phosphatase may be more helpful but is still imperfect
Pretreatment countsANC ≥1.5 x 10^9/L, platelets ≥100 x 10^9/L, Hgb ≥10 g/dL for first dose
Subsequent-dose countsPlatelets ≥50 x 10^9/L, Hgb ≥8 g/dL

Radiation Safety Pearls

223Ra has a half-life of about 11.4 days. After administration, blood, urine, and stool are radioactive.
Practical counseling includes gloves for handling contaminated fluids/laundry, closed-lid toilet flushing, separate washing of stained clothes, and awareness that airport sensors may detect residual activity. The deck notes no routine post-treatment imaging is used.

ERA-223 and PEACE-3

TrialSchemaMain resultTakeaway
ERA-223Abiraterone/prednisone +/- Ra-223No improvement in symptomatic skeletal EFS; fractures 29% vs 11%Do not give abiraterone and Ra-223 together
PEACE-3Enzalutamide +/- Ra-223 in first-line mCRPCrPFS 19.4 vs 16.4 mo, HR 0.69; OS immature; grade 3+ AEs 66% vs 56%Adding Ra-223 to enzalutamide improves rPFS, but bone protection is required

PART III — 177LU-DOTATATE (LUTATHERA)

Indication and Mechanism

177Lu-DOTATATE is indicated for SSTR-positive gastroenteropancreatic neuroendocrine tumors. It is a radiolabeled somatostatin analog that binds somatostatin receptors, is internalized, and then delivers beta radiation to the tumor and nearby cells.

NETTER-1

NETTER-1 randomized 229 patients with advanced, well-differentiated, progressive SSTR+ midgut NETs to 4 infusions of 177Lu-DOTATATE 7.4 GBq every 8 weeks plus octreotide LAR 30 mg vs high-dose octreotide LAR 60 mg every 4 weeks. PFS HR was 0.18, 20-month PFS was 65.2% vs 10.8%, and ORR was 18% vs 3%. Median OS was 48.0 vs 36.3 months, not statistically significant, but clinically favorable. This is the landmark trial that established Lutathera as standard of care.

NETTER-2

NETTER-2 moved PRRT earlier. In 226 patients with newly diagnosed advanced SSTR+, well-differentiated, higher-grade G2/G3 GEP-NETs, 177Lu-DOTATATE 7.4 GBq every 8 weeks x4 plus octreotide LAR 30 mg significantly improved median PFS from 8.5 to 22.8 months (HR 0.276) and improved ORR from 9.3% to 43.0%. The deck frames this as the first phase III trial showing first-line radioligand benefit in any solid tumor.

NETTER-1 vs NETTER-2

FeatureNETTER-1NETTER-2
Tumor groupMidgut NET onlyAll GEP-NETs
GradeGrade 1-2Grade 2-3
Line of therapyPost-SSA progressionFirst line
PFS HR0.180.276
ORR18%43%

Administration Pearl

Standard course is 4 doses every 8 weeks.
Antiemetics are given, and L-lysine / L-arginine amino acid infusion should start 30 minutes before therapy and continue during and for at least 3 hours after to help protect kidneys.

PART IV — 177LU-PSMA-617 AND RELATED PSMA-RLT STRATEGIES

VISION: Post-Taxane mCRPC

VISION randomized 831 patients with PSMA-positive mCRPC who had progressed after taxane therapy to 177Lu-PSMA-617 7.5 GBq every 6 weeks x6 plus SOC vs SOC alone. Median OS improved from 11.3 to 15.3 months, and image-based PFS improved from 3.4 to 8.7 months. Grade 3+ toxicity was higher (53% vs 38%), but QOL was not adversely affected.

PSMAfore: Taxane-Naive mCRPC

PSMAfore tested 177Lu-PSMA-617 200 mCi (+/-10%) every 6 weeks x6 against a change in ARPI in taxane-naive mCRPC. rPFS improved from 5.55 to 9.30 months in the primary analysis, and to 11.60 vs 5.59 months in the updated analysis. Grade 3-5 AEs were actually lower with Lu-PSMA (36% vs 48%).

TheraP and ENZA-P

TrialComparatorMain resultTakeaway
TheraPCabazitaxel vs Lu-PSMA-617PSA response 66% vs 37%; grade 3-4 AEs 33% vs 53%Strong phase II support for Lu-PSMA vs cabazitaxel in selected mCRPC
ENZA-PEnzalutamide +/- adaptive Lu-PSMA-617PSA-PFS 13 vs 8 months; grade 3+ toxicity similarUpfront combination strategy is promising in taxane-naive mCRPC

Moving Earlier: PSMAddition and LUNAR

TrialPopulationMain resultCurrent interpretation
PSMAdditionPSMA+ mHSPC, phase IIIrPFS HR 0.72; PSA nadir <0.2 at 48 weeks 87.4% vs 74.9%; OS trend but not yet significantFirst phase III targeted RLT trial in hormone-sensitive metastatic prostate cancer
LUNAROligorecurrent hormone-sensitive prostate cancerPFS 17.6 vs 7.4 months, HR 0.37; hormone-therapy-free survival 24.3 vs 14.1 monthsProof of concept that PSMA-RLT + SBRT can treat visible and occult disease together
LUNAR pearl: this was the first randomized trial of PSMA-targeted radioligand therapy in hormone-sensitive oligorecurrent prostate cancer. It is an important “where the field is going” study rather than a current universal standard.

Retreatment / Sequencing

Retrospective studies such as RALU, REALITY, and German extended-therapy series suggest that rechallenge or additional Lu-PSMA can be feasible in selected patients, with the main risks being myelosuppression and renal function decline. This remains an individualized area rather than a fixed standard.

PART V — ACCESS, STAFFING, AND WHO SHOULD OWN RPT

Access Is a Major Clinical Problem

The lecture strongly emphasizes that there is a real need to expand access beyond academic centers. The geographic mismatch between where patients live and where RPT is available is a major implementation problem, and one of the main reasons radiation oncology should remain involved.

Radiation Oncology vs Nuclear Medicine

GroupAdvantagesLimitations
Radiation OncologyCommunity footprint, oncology referral relationships, can combine EBRT + RPT, may be well positioned for dosimetry integrationOften lacks PET/SPECT infrastructure, hot lab, radioactive bathroom, or AU-certified physicians
Nuclear MedicineImaging expertise, theranostic infrastructure, more direct radiopharma experienceLess community reach, often less longitudinal toxicity management and insurance coordination, less experience with EBRT integration

Program-Building Essentials

Minimal program ingredients from the deck:
  • Staffing: nuclear medicine technologist or RTT, nurse, APP support, financial counselor, qualified medical physicist, and an Authorized User
  • Infrastructure: hot lab with dose calibrator and GM meter, dedicated administration room, and a radioactive bathroom
  • Follow-up capability: lab monitoring, toxicity management, coordination with medical oncology, and transfusion support when needed

Practical Patient Counseling for Lu-PSMA-Type Therapy

Common counseling points from the administration slide:
  • Increase oral fluids and void frequently to reduce bladder dose
  • Limit close contact with others for 3 days
  • Sleep in a separate bedroom for 3 days
  • Avoid sexual activity for 7 days
  • Use contraception during therapy and for 14 weeks after the last dose

PART VI — DOSIMETRY: THE BIG UNRESOLVED FRONTIER

Why Dosimetry Matters

EBRT is prescribed to a point or volume dose.
RPT is usually prescribed like systemic therapy, by injected activity, body weight, or surface area.
That mismatch is the core reason dosimetry remains such a hot topic.

Arguments For and Against Patient-Specific Dosimetry

Potential advantagePotential drawback
Tumor uptake is heterogeneous across lesions and across patientsTreatment complexity increases substantially
Normal tissue dose also varies by patientCost rises for already expensive therapies
Injected activity could theoretically be adapted to improve therapeutic ratioCurrent fixed-activity regimens already produce major clinical benefit
Could optimize combination RPT + EBRT plansWe still need prospective trials proving dosimetry changes outcomes

General Workflow

The workflow shown is: SPECT/CT imaging -> ROI contouring -> time integration -> dose calculation -> dose evaluation.
Post-therapy quantitative SPECT/CT is typically performed at about 3-5 days after administration, after calibration of the camera system.

What the Early Outcome Data Suggest

Multiple studies in Lu-PSMA showed that whole-body tumor absorbed dose correlates with PSA response, and in newer series also with bPFS and OS. The lecture also highlighted a real-world experience in which 50% of patients undergoing dosimetry had a management change, including adding SBRT to heterogeneous progression, consolidating residual disease, switching therapy for poor uptake, or holding treatment when response was excellent.
Exam framing: dosimetry is one of the most plausible places where radiation oncology can add unique value to radiopharmaceutical programs, but it is not yet a universally proven standard-of-care requirement.

CROSS-CUTTING HIGH-YIELD POINTS

  • Theranostics integrates imaging, patient selection, dosimetry, response assessment, and therapy in one target-based workflow.
  • Therapeutic effect comes from absorbed dose, not from the carrier molecule.
  • Alpha emitters have high LET and short path length but problematic heterogeneity and harder dosimetry.
  • I-131 is the historical proof-of-principle that systemic targeted RT can improve survival.
  • Radium-223 improves OS in bone-only mCRPC and is not just a palliative drug.
  • ALSYMPCA numbers to know: OS 14.9 vs 11.3 months; time to skeletal event 15.6 vs 9.8 months.
  • ERA-223: do not combine abiraterone and Ra-223 concurrently because fractures increased and efficacy did not improve.
  • PEACE-3: enzalutamide + Ra-223 improves rPFS, but bone-protective agents are needed.
  • 177Lu-DOTATATE is standard for progressive SSTR+ midgut NETs from NETTER-1.
  • NETTER-2 is a major practice-shaping trial because it moves RLT into the first-line setting for higher-grade GEP-NETs.
  • 177Lu-DOTATATE administration pearl: give amino acids with lysine/arginine beginning 30 minutes before and continuing for at least 3 hours after infusion.
  • VISION established Lu-PSMA-617 as an OS-improving therapy in post-taxane PSMA+ mCRPC.
  • PSMAfore supports Lu-PSMA before taxane in selected mCRPC.
  • TheraP is the memorable cabazitaxel-vs-Lu-PSMA phase II comparison.
  • PSMAddition is the first phase III targeted RLT trial in mHSPC and already shows rPFS benefit.
  • LUNAR is the first randomized PSMA-RLT trial in oligorecurrent hormone-sensitive prostate cancer and is a major “future-direction” trial.
  • Radiation oncology has a real role in improving access to RPT, especially in the community and in combining RPT with EBRT.
  • Program needs include an AU, hot lab, radioactive bathroom, trained technologists, physics support, and strong coordination infrastructure.
  • Dosimetry is promising but not fully validated; it may personalize activity selection and EBRT integration, but prospective trials are still needed.

CONSOLIDATED DOSE / ADMINISTRATION TABLE

Agent / trialDose / scheduleWhy it matters
Radium-223 (ALSYMPCA)50 kBq/kg q4 weeks x 6Landmark bone-only mCRPC survival regimen
177Lu-DOTATATE (NETTER-1 / 2)7.4 GBq q8 weeks x 4Standard PRRT backbone for SSTR+ GEP-NET
Octreotide support30 mgUsed with DOTATATE in both NETTER trials
Lu-DOTATATE control armOctreotide LAR 60 mg q4 weeksNETTER comparator
Lu-DOTATATE renal protectionAmino acids starting 30 min before, continue during and >=3 h afterLysine/arginine infusion to reduce kidney dose
177Lu-PSMA-617 (VISION)7.5 GBq q6 weeks x 6Landmark post-taxane Pluvicto schedule
177Lu-PSMA-617 (PSMAfore)200 mCi (+/-10%) q6 weeks x 6Taxane-naive mCRPC regimen
ENZA-P adaptive Lu-PSMA2-4 doses at 7.5 GBq q6-8 weeksPhase II upfront combination strategy
PSMAddition7.4 GBq q6 weeks x 6Phase III mHSPC intensification schedule
LUNAR177Lu-PNT2002 6.8 GBq x 2 cycles, 8 weeks apartProof-of-concept oligorecurrent HSPC combination with SBRT
I-131Half-life 8 days; about 2 mm penetrationHistoric thyroid theranostic platform
Y-90Half-life 2.5 days; about 2 cm penetrationFoundational liver radioembolization isotope
Ra-223 safetyHalf-life 11.4 daysExplains prolonged radiation-safety counseling

KEY LANDMARK TRIALS (memorize)

TrialDisease / settingOne-line takeaway
ALSYMPCABone-only mCRPCRadium-223 improves OS and delays skeletal events
ERA-223mCRPCAbiraterone + Ra-223 increased fractures and did not help efficacy
PEACE-3First-line mCRPC with bone metastasesAdding Ra-223 to enzalutamide improves rPFS, with bone protection required
NETTER-1Progressive SSTR+ midgut NETEstablished 177Lu-DOTATATE as standard PRRT therapy
NETTER-2First-line higher-grade GEP-NETMoved 177Lu-DOTATATE into the first-line setting with major PFS and ORR gains
VISIONPost-taxane PSMA+ mCRPC177Lu-PSMA-617 improves OS and PFS
PSMAforeTaxane-naive mCRPCPluvicto beats ARPI switch for rPFS with favorable toxicity
TheraPmCRPC, cabazitaxel comparisonLu-PSMA improves PSA response and lowers severe toxicity vs cabazitaxel
ENZA-PTaxane-naive mCRPCUpfront Pluvicto + enzalutamide improves PSA-PFS
PSMAdditionmHSPCFirst phase III targeted RLT trial in hormone-sensitive metastatic prostate cancer
LUNAROligorecurrent hormone-sensitive prostate cancerFirst randomized PSMA-RLT trial in early oligometastatic hormone-sensitive disease
RALU / REALITY / extended Lu-PSMA seriesRetreatment / rechallengeRetreatment may be feasible, but evidence remains retrospective
Violet / Fitzpatrick / GrkovskiLu-PSMA dosimetryWhole-body tumor absorbed dose correlates with response and outcomes